Vincent Zucconi’s Post

How are biotech companies achieving scale whilst managing significant market disruption? In our new "Scaling innovation in advanced therapy manufacturing" series, Chris Hamilton speaks with Kwok Pang to explore expansion within the life sciences sector, taking a closer look at adthera bio to explore their growth journey. Watch the first episode here: https://lnkd.in/emTSzece #LifeSciences #Biotech #ExecutiveSearch

🚀 Big move in Biotech! Biogen expands horizons beyond neurology with a bold $1.15 billion acquisition of HI-Bio. A pivotal moment for Biogen, pursuing diversification by embracing the potential of immune-focused therapies. 🧬 ➡️ Felzartamab, HI-Bio's lead, is making waves in the fight against kidney conditions, gearing up for Phase 3. This strategic leap is all about innovation and resilience, thrusting Biogen into the immunology spotlight without swaying their financial stability for 2024. 💼💸 Executive leaders, innovators, and tech experts - this is a game-changer worth watching! How will this shape the future of patient care? 💡🤔 #Biogen #HealthTech #Innovation

Today, TrialKey attended the BioConnect: Australia-Taiwan Biotech Forum at the Centre for Eye Research Australia (CERA), hosted by Southern Taiwan Science Park, the Development Center for Biotechnology, and Australian Trade and Investment Commission (Austrade). The event brought together 12 pioneering Taiwanese biotech companies, including ACRO Biomedical Co., Ltd., KriSan Biotech Co., Ltd., and UNICOCELL Biomed, each advancing innovative solutions from regenerative medicine to RNA therapeutics. TrialKey had the opportunity to engage in one-on-one meetings with these companies, showcasing our AI-powered biostatistical validation and clinical trial simulation services. This experience underscored our commitment to bridging international clinical research partnerships and exploring collaborative synergies. Book a demo: https://appt.link/minhthu Marketing and Opyl investor enquiries: bernice@trialkey.ai #biotechnology #clinicalresearch #biotech #medtech #healthtech #regenerativemedicine #australiabiotech #biostatistics #clinicaltrials #austrade #bioconnect #ai

🧬 The Hanson Wade Group’s 4th Annual iPSC Drug Development & Manufacturing Conference in #Boston is in full swing! Our Principal Product Manager, Bar Makovoz, PhD, will be presenting on “An Advanced Biomanufacturing Technology to Scale Production of Autologous iPSC-Based Cell Therapies,” at 11:45 AM EDT on Thursday, October 3. Join us for this session on Conference Day 2, part of the Manufacturing & Analytical Development track. 🔬 Key topics to be highlighted include: 🔷 Automated cell culture, imaging, liquid handling, and cell removal: driven by AI-based in-process characterization and decision making 🔷 Closed cassette-based GMP system in early development 🔷 60 unique and clonal iPSC lines generated from a diversity of donors, with demonstrated successful differentiation in the hands of collaborators We’re excited to contribute to the conversation around the evolution of iPSC-based cell therapies and how these advancements will shape the future of personalized regenerative medicine. 🚀 👉 See the full agenda here: bit.ly/4eM74Kl #HansonWadeGroup #RegenMed #Biotech #DrugDevelopment #Therapeutics #AI #AIinHealthcare #MachineLearning #PersonalizedMedicine #YourCellsYourCure #CellinoBio

Interested in cloud-connected upstream process development and optimization. Learn more by downloading Culture Biosciences’ white paper. #cloudconnectivity #processdevelopment #bioreactor #bioprocess

How much do you think was the valuation of the single-cell multi-omics market in Europe alone in 2023? $350 million How much is it expected to be worth by 2033 though? $𝟭.𝟳𝟭 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 According to a report from BIS Research, this takes into account the growing interest in personalized medicine and usage of a multi-omic approach in drug development. What does this mean for us here in Cambridge? As the biotech hub of the country with new spin-offs and start-ups innovating in the space every month, we can hopefully look forward to more rounds of funding and real investment into innovation and scientific development. Have you seen any promising start-ups that you expect will be the next big thing? Curious to know more about what the start-up life is like? Let's connect to talk about all things Omic! #omics #cambridge #startuplife

Culture Biosciences’ cloud-connected, high-throughput bioreactor platform can reproducibly process and optimize CHO cell culture experiments with scalable results. Data presented in this white paper by engineers in Culture’s Cloud Lab demonstrate upstream bioprocesses to develop, optimize and scale cell culture processes. With access to significant bioreactor capacity leveraging advanced analytical software to generate insights faster, clients working with Culture can spend their time focusing on what matters most: developing critical therapeutics for the patients who need them. #processdevelopment #processoptimization #mAb #CHO https://lnkd.in/eqghbyz4

Culture Biosciences’ cloud-connected, high-throughput bioreactor platform can reproducibly process and optimize CHO cell culture experiments with scalable results. Data presented in this white paper by engineers in Culture’s Cloud Lab demonstrate upstream bioprocesses to develop, optimize and scale cell culture processes. With access to significant bioreactor capacity leveraging advanced analytical software to generate insights faster, clients working with Culture can spend their time focusing on what matters most: developing critical therapeutics for the patients who need them. #processdevelopment #processoptimization #mAb #CHO https://lnkd.in/eqghbyz4

The 8th IPF Summit will be taking place in just 6 weeks, will you be joining the pulmonary fibrosis community in Boston? The IPF Summit is the definitive forum for IPF therapeutic developers, key opinion leaders, and innovators to unite to discuss the most pressing challenges from harnessing emerging biological understanding for targets, to applying novel and evolving in vivo and in vitro models, to assessing the evolving patient populations. This is your end-to-end, one-stop shop, for your team to take away critical insights to apply to your pulmonary fibrosis research and pipelines. Take a look at the full event guide here to view the 40+ sessions, 12+ hours of networking, the dedicated Ambassador's Evening, and 6 deep-dive workshops: https://lnkd.in/e7JXGMZR With 6 weeks to go, here's a💡Session Spotlight💡: - Analyzing the Design of a Phase 3 Trial for Inhaled Treprostinil with Peter Smith, Vice President, Product Development, United Therapeutics Corporation - ADC-Mediated Depletion of Pathogenic Fibroblasts Ameliorates Pulmonary Fibrosis with Adam Freund, Chief Executive Officer, Arda Therapeutics - Deciphering Patient Heterogeneity Leveraging AI & Novel Models to Segment Heterogeneous Disease Populations & Unlock Personalized Medicine in IPF with marilyn glassberg, Professor & Chair Department of Medicine, Loyola University - From Symptom to Surrogate Endpoint: Where Does Cough Fit in IPF Drug Development with Toby Maher, Professor, USC Hope to see you in Boston with the pulmonary fibrosis community! #IPFSummit #pulmonaryfibrosis #IPF #lunghealth #respiratoryhealth #respiratory #interstitiallungdiseases #ILD #ADCs

Advancing #Nanobody Discovery with Measurable Impact 🔬 How do you address the challenges of precision medicine with speed and efficiency? Nanobody technology is paving the way for breakthroughs in diagnostics, therapeutics, and advanced research. However, effectively harnessing this potential requires a robust, efficient discovery process. Jotbody’s Nanobody Discovery Service is designed to meet the demands of today’s biomedical landscape: • 12 weeks: A streamlined development process, reducing timelines by over 60%. • 20+ unique sequences: Sourced from camels, alpacas, llamas, and sharks for a comprehensive and diverse nanobody library. • Up to 40% cost savings: Optimized workflows to control expenses without compromising quality. • Targeted precision: Tailored nanobody solutions for challenging applications, including mutating pathogens and hard-to-reach molecular targets. 📊 With expertise in nanobody development, Jotbody helps you solve complex challenges efficiently, delivering measurable results to support your innovation. 👉 Learn more about our Nanobody Discovery Service here: https://lnkd.in/gkkpyWbU We welcome professionals in diagnostics, therapeutics, and research to connect and explore tailored solutions for their specific needs. #NanobodyDiscovery #PrecisionMedicine #BiotechInnovation #AdvancedResearch #Jotbody